CYAD - Celyad Oncology receives Nasdaq non-compliance notice
2023-04-04 16:21:30 ET
- Celyad Oncology ( NASDAQ: CYAD ) said on Tuesday that the biotechnology company received a Nasdaq notice over failure to maintain continued listing requirements under the stock exchange's rules.
- The stock exchange requires a listed company to maintain stockholders' equity of at least $10M, and the company failed to meet the requirement based on the company's Form 20-F for the period ended Dec. 31, 2022.
- Celyad Oncology has 45 calendar days, or until May 15, to submit a plan to regain compliance with the requirement.
- CYAD shares were trading +2.77% post-market.
- Source: Press Release
For further details see:
Celyad Oncology receives Nasdaq non-compliance notice